Bijoy Telivala, MD
Hematology & Oncology · Jacksonville, FLNPI 1790935153
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,540 of the $3,717 with a category attached, or 68.3%. Pfizer accounts for 71.6% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2019 at $2,654 and has fallen 80.5% since, to $517 in 2025. That places this record below the midpoint for hematology & oncology clinicians in FL, where the typical reported total is $3,884.
Across 63 payments — averaging $58.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$3K
- ASD Specialty Healthcare, LLC$155
- Seagen Inc.$141
- Novartis$117
- Avyxa Pharma, LLC$58
- Johnson & Johnson$48
- plus $535 from 25 others
Across 167 payments — averaging $1842.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$127K
- AstraZeneca$51K
- E.r. Squibb & Sons, L.L.C.$46K
- Astrazeneca UK Limited$28K
- Pharmacyclics LLC, An Abbvie Company$26K
- Incyte Corporation$20K
- plus $10K from 2 others
What the payments were for
- Speaking & faculty fees$2,54068%
- Food & beverage$1,09830%
- Education$782%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 16 | $2,663 |
| ASD Specialty Healthcare, LLC | 2 | $155 |
| Seagen Inc. | 2 | $141 |
| Novartis | 8 | $117 |
| Avyxa Pharma, LLC | 1 | $58 |
| Johnson & Johnson | 3 | $48 |
| Sun Pharmaceutical Industries Inc. | 1 | $47 |
| Fennec Pharmaceuticals, Inc. | 2 | $42 |
| GSK | 3 | $41 |
| Incyte Corporation | 2 | $34 |
| Bayer | 2 | $30 |
| Astellas Pharma US Inc | 2 | $29 |
| Octapharma USA, Inc. | 1 | $27 |
| Rigel Pharmaceuticals, Inc. | 1 | $26 |
| ADC Therapeutics America, Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Tempus AI, Inc | 1 | $21 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Merck | 1 | $16 |
| Innate Pharma, Inc | 1 | $16 |
| Springworks Therapeutics, Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Taiho Oncology, Inc. | 1 | $14 |
| Immunocore Limited | 1 | $13 |
| Karyopharm Therapeutics Inc. | 1 | $12 |
| Gilead | 1 | $12 |
| Global Blood Therapeutics, Inc. | 1 | $12 |
| Lexicon Pharmaceuticals, Inc. | 1 | $11 |
| Aurobindo Pharma USA, Inc. | 1 | $11 |
| Genentech USA, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IBRANCE$2,540
How this compares
$3,717 in reported general payments places this provider in the 45th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 19 | $272,525 |
| JakafiRuxolitinib Phosphate | 13 | $218,074 |
| ImbruvicaIbrutinib | 12 | $173,062 |
| ErivedgeVismodegib | 11 | $148,316 |
| IbrancePalbociclib | 11 | $128,084 |
| Abiraterone Acetate | 67 | $100,967 |
| XtandiEnzalutamide | 12 | $100,677 |
| EliquisApixaban | 103 | $70,808 |
| ValacyclovirValacyclovir Hcl | 34 | $928 |
| Hydroxyurea | 22 | $708 |
| Ondansetron Hcl | 68 | $510 |
| Prednisone | 124 | $403 |
| Gabapentin | 27 | $354 |
| Letrozole | 14 | $303 |
| Anastrozole | 19 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $48 | $272,52519 claims |
| Incyte CorporationJakafi | $34 | $218,07413 claims |
| PfizerIbrance, Eliquis | $2,663 | $198,892114 claims |
| Genentech USA, Inc.Erivedge | $11 | $148,31611 claims |
| Astellas Pharma US IncXtandi | $29 | $100,67712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 694 hematology & oncology providers in Florida.
Other hematology & oncology in Jacksonville
- Edith PerezJacksonville$1.1M
- Vamsidhar VelchetiJacksonville$966K
- Arnab BasuJacksonville$440K
- Sikander AilawadhiJacksonville$179K
- James ForanJacksonville$164K
- Asher Chanan KhanJacksonville$109K
- Martin DietrichRockledge$6.2M
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Edgardo SantosFort Lauderdale$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.